GALXC
DEAD

Serial Number

87315569

Owner

Dicerna Pharmaceuticals, Inc.

Attorney

Glenn A. Gundersen

Filing Date

Jan 27, 2017

Add to watchlist:

No watchlists yet
View on USPTO

GALXC Trademark

Serial Number: 87315569

GALXC is a trademark filed by Dicerna Pharmaceuticals, Inc. on January 27, 2017. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Dicerna Pharmaceuticals, Inc. (33 trademarks)

Lexington, MA 02421

Entity Type: 03

Trademark Details

Filing Date

January 27, 2017

Registration Date

Not Registered

Published for Opposition

December 19, 2017

Goods & Services

Custom manufacture of oligonucleotides for use in genetic research, pharmaceutical therapies, medical research and treatment of various conditions and disorders

Oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, and viral infections; Oligonucleotide delivery agents for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, and viral infections; Oligonucleotide compounds for use in the targeted delivery of RNAi therapy; Oligonucleotide delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceutical and therapeutic agents intravenously or subcutaneously for use in targeted pharmaceutical therapies for a wide range of medical purposes; drug delivery agents consisting of oligonucleotide compounds that facilitate the delivery of a wide range of pharmaceutical based therapies

Research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, and viral infections; research and development of pharmaceutical preparations for the treatment of liver-based disorders; research and development of oligonucleotide compounds for targeted gene silencing; research and development of oligonucleotide drug delivery platforms for use in the treatment of rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, and viral infections

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Mar 22, 2021 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Mar 22, 2021 ABN6
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 25, 2021 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 25, 2021 TCCA
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Feb 25, 2021 COAR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 19, 2020 EXRA
SOU EXTENSION 5 GRANTED
Aug 18, 2020 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Aug 18, 2020 AITU
SOU EXTENSION 5 FILED
Aug 12, 2020 EXT5
SOU TEAS EXTENSION RECEIVED
Aug 12, 2020 EEXT
ASSIGNED TO EXAMINER
Jun 4, 2020 DOCK
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 15, 2020 EXRA
SOU EXTENSION 4 GRANTED
Feb 13, 2020 EX4G
SOU EXTENSION 4 FILED
Feb 13, 2020 EXT4
SOU TEAS EXTENSION RECEIVED
Feb 13, 2020 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 14, 2019 EXRA
SOU EXTENSION 3 GRANTED
Aug 12, 2019 EX3G
SOU EXTENSION 3 FILED
Aug 12, 2019 EXT3
SOU TEAS EXTENSION RECEIVED
Aug 12, 2019 EEXT
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 10, 2019 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 10, 2019 REAP
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 12, 2019 EXRA
SOU EXTENSION 2 GRANTED
Jan 10, 2019 EX2G
SOU EXTENSION 2 FILED
Jan 10, 2019 EXT2
SOU TEAS EXTENSION RECEIVED
Jan 10, 2019 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 15, 2018 EXRA
SOU EXTENSION 1 GRANTED
Aug 13, 2018 EX1G
SOU EXTENSION 1 FILED
Aug 13, 2018 EXT1
SOU TEAS EXTENSION RECEIVED
Aug 13, 2018 EEXT
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Jul 23, 2018 EWAF
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 13, 2018 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 19, 2017 NPUB
PUBLISHED FOR OPPOSITION
Dec 19, 2017 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 29, 2017 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 15, 2017 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 15, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 15, 2017 CRFA
ASSIGNED TO LIE
Nov 14, 2017 ALIE
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Nov 2, 2017 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Aug 7, 2017 GNFN
FINAL REFUSAL E-MAILED
Aug 7, 2017 GNFR
FINAL REFUSAL WRITTEN
Aug 7, 2017 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 28, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 27, 2017 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 27, 2017 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 25, 2017 GNRN
NON-FINAL ACTION E-MAILED
Apr 25, 2017 GNRT
NON-FINAL ACTION WRITTEN
Apr 25, 2017 CNRT
ASSIGNED TO EXAMINER
Apr 24, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 31, 2017 NWOS
NEW APPLICATION ENTERED
Jan 31, 2017 NWAP